dalteparin has been researched along with Adenocarcinoma in 24 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the study, the effect of dalteparin on pulmonary adenocarcinoma A549 cell line was observed in vitro." | 7.74 | The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro. ( Chen, X; Qu, X; Xiao, W; Zhou, S, 2008) |
| " In the study, the effect of dalteparin on pulmonary adenocarcinoma A549 cell line was observed in vitro." | 3.74 | The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro. ( Chen, X; Qu, X; Xiao, W; Zhou, S, 2008) |
| " The maximum tolerated dose (MTD) of lenalidomide given in combination with gemcitabine was defined as the highest dose level at which no more than one out of four (25%) subjects experiences a dose-limiting toxicity (DLT)." | 2.80 | A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. ( Liljefors, M; Rossmann, E; Ullenhag, GJ, 2015) |
| "Patients with oesophageal cancer undergoing neoadjuvant chemoradiotherapy and surgery are at substantial risk of thromboembolic and bleeding events throughout all stages of treatment." | 1.56 | Thromboembolic and bleeding complications in patients with oesophageal cancer. ( Büller, HR; Hovenkamp, A; Hulshof, MCCM; Kamphuisen, PW; Middeldorp, S; Mulder, FI; van Berge Henegouwen, MI; van Es, N; van Laarhoven, HWM, 2020) |
| "HT29 human colorectal cancers were implanted in dorsal skinfold window chambers in athymic mice." | 1.42 | Microvascular effects of the low molecular weight heparins in a colorectal xenograft model: an intravital microscopy study. ( Ceelen, W; Debergh, I; Pattyn, P, 2015) |
| "The risk of prostate cancer-specific mortality (PCSM) was compared between the AC and non-AC groups." | 1.38 | Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. ( Carroll, PR; Chan, JM; Choe, KS; Cowan, JE; D'Amico, AV; Liauw, SL, 2012) |
| "The pattern of breast cancer metastasis may be determined by interactions between CXCR4 on breast cancer cells and CXCL12 within normal tissues." | 1.34 | Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? ( Ali, S; Eldaly, H; Harvey, JR; Kirby, JA; Lennard, TW; Mellor, P, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Mulder, FI | 1 |
| Hovenkamp, A | 1 |
| van Laarhoven, HWM | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Hulshof, MCCM | 1 |
| van Berge Henegouwen, MI | 1 |
| Middeldorp, S | 1 |
| van Es, N | 1 |
| Debergh, I | 1 |
| Pattyn, P | 1 |
| Ceelen, W | 1 |
| Zhong, GX | 1 |
| Gong, Y | 1 |
| Yu, CJ | 1 |
| Wu, SF | 1 |
| Ma, QP | 1 |
| Wang, Y | 1 |
| Ren, J | 1 |
| Zhang, XC | 1 |
| Yang, WH | 1 |
| Zhu, W | 1 |
| Zhuang, X | 1 |
| Qiao, T | 1 |
| Xu, G | 1 |
| Yuan, S | 1 |
| Zhang, Q | 1 |
| Chen, X | 2 |
| Carmazzi, Y | 1 |
| Iorio, M | 1 |
| Armani, C | 1 |
| Cianchetti, S | 1 |
| Raggi, F | 1 |
| Neri, T | 1 |
| Cordazzo, C | 1 |
| Petrini, S | 1 |
| Vanacore, R | 1 |
| Bogazzi, F | 1 |
| Paggiaro, P | 1 |
| Celi, A | 1 |
| Hoe, V | 1 |
| Kinnear, N | 1 |
| Christidis, D | 1 |
| O'Connell, H | 1 |
| Martín Guerra, JM | 1 |
| Asenjo, MM | 1 |
| Dueñas Gutiérrez, CJ | 1 |
| Gil González, I | 1 |
| Pelzer, U | 1 |
| Sinn, M | 1 |
| Stieler, J | 1 |
| Riess, H | 1 |
| Papageorgiou, C | 1 |
| Vandreden, P | 1 |
| Marret, E | 1 |
| Bonnet, F | 1 |
| Robert, F | 1 |
| Spyropoulos, A | 1 |
| Galea, V | 1 |
| Elalamy, I | 1 |
| Hatmi, M | 1 |
| Gerotziafas, GT | 1 |
| Burtness, B | 1 |
| Powell, M | 1 |
| Catalano, P | 1 |
| Berlin, J | 1 |
| Liles, DK | 1 |
| Chapman, AE | 1 |
| Mitchell, E | 1 |
| Benson, AB | 1 |
| Kirienko, AI | 1 |
| Andriiashkin, VV | 1 |
| Lebedev, IS | 1 |
| Bagirian, MS | 1 |
| Babakova, NA | 1 |
| Mitma, AA | 1 |
| Varghese, JG | 1 |
| Witt, D | 1 |
| Zarich, SW | 1 |
| Byrne, M | 2 |
| Reynolds, JV | 1 |
| O'Donnell, JS | 1 |
| Keogan, M | 1 |
| White, B | 1 |
| Murphy, S | 1 |
| Maher, SG | 1 |
| Pidgeon, GP | 1 |
| Abu Arab, W | 1 |
| Kotb, R | 1 |
| Sirois, M | 1 |
| Rousseau, E | 1 |
| Choe, KS | 1 |
| Cowan, JE | 1 |
| Chan, JM | 1 |
| Carroll, PR | 1 |
| D'Amico, AV | 1 |
| Liauw, SL | 1 |
| Pross, M | 2 |
| Lippert, H | 2 |
| Nestler, G | 2 |
| Kuhn, R | 1 |
| Langer, H | 2 |
| Mantke, R | 1 |
| Schulz, HU | 2 |
| Zacharski, LR | 1 |
| Misselwitz, F | 1 |
| Krüger, S | 1 |
| Halangk, W | 1 |
| Ullenhag, GJ | 1 |
| Rossmann, E | 1 |
| Liljefors, M | 1 |
| Xiao, W | 1 |
| Qu, X | 1 |
| Zhou, S | 1 |
| Moore, A | 1 |
| Lau, E | 1 |
| Yang, C | 1 |
| Mackool, B | 1 |
| Kuter, DJ | 1 |
| Matikas, A | 1 |
| Vardakis, N | 1 |
| Souglakos, J | 1 |
| Georgoulias, V | 1 |
| Auer, R | 1 |
| Scheer, A | 1 |
| Wells, PS | 1 |
| Boushey, R | 1 |
| Asmis, T | 1 |
| Jonker, D | 1 |
| Carrier, M | 1 |
| Harvey, JR | 1 |
| Mellor, P | 1 |
| Eldaly, H | 1 |
| Lennard, TW | 1 |
| Kirby, JA | 1 |
| Ali, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Lenalidomide and Gemcitabine as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer[NCT01547260] | Phase 1/Phase 2 | 34 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for dalteparin and Adenocarcinoma
| Article | Year |
|---|---|
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antige | 2016 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Pro | 2015 |
The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial.
Topics: Adenocarcinoma; Aged; Canada; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule | 2011 |
21 other studies available for dalteparin and Adenocarcinoma
| Article | Year |
|---|---|
Thromboembolic and bleeding complications in patients with oesophageal cancer.
Topics: Adenocarcinoma; Aged; Anticoagulants; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; E | 2020 |
Microvascular effects of the low molecular weight heparins in a colorectal xenograft model: an intravital microscopy study.
Topics: Adenocarcinoma; Animals; Anticoagulants; Colorectal Neoplasms; Enoxaparin; HT29 Cells; Humans; Immun | 2015 |
Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism.
Topics: Actin Cytoskeleton; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Adhesion; Cell Movement; C | 2015 |
Combination of nadroparin with radiotherapy results in powerful synergistic antitumor effects in lung adenocarcinoma A549 cells.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Basigin; Cell Movement; Cell Prolifer | 2016 |
The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines.
Topics: Adenocarcinoma; Anticoagulants; Apoptosis; Carcinoma, Squamous Cell; cdc25 Phosphatases; Cell Cycle | 2012 |
Rectus sheath haematoma causing ureteric obstruction.
Topics: Adenocarcinoma; Aged, 80 and over; Anticoagulants; Colonic Neoplasms; Enoxaparin; Female; Gastrointe | 2018 |
Synchronous Cardiopulmonary Consequences of the Hypercoagulable State Associated With Cancer.
Topics: Adenocarcinoma; Anticoagulants; Brain Ischemia; Computed Tomography Angiography; Endocarditis, Non-I | 2019 |
[Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?].
Topics: Adenocarcinoma; Ambulatory Care; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Enoxa | 2013 |
Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Anticoagulants; Blood Coagulation; Blood Coagulation T | 2013 |
[Thrombosis of inferior vena cava suprarenal portion and right atrium in case of stomach cancer].
Topics: Adenocarcinoma; Echocardiography, Three-Dimensional; Enoxaparin; Female; Fibrinolytic Agents; Gastre | 2014 |
Stroke and a valvular lesion in a patient with stage IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Anticoagulants; Cerebellum; Diagnosis, Differential; E | 2016 |
Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery.
Topics: Adenocarcinoma; Adult; Aged; Anticoagulants; Biomarkers; Carcinoma, Squamous Cell; Combined Modality | 2010 |
Concentration- and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Prolif | 2011 |
Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chemoprevention; Clopidogre | 2012 |
Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study.
Topics: Abdominal Neoplasms; Adenocarcinoma; Animals; Anticoagulants; Disease Models, Animal; Dose-Response | 2004 |
Heparin treatment of malignancy: the case for clinical trials in colon cancer.
Topics: Adenocarcinoma; Animals; Anticoagulants; Clinical Trials as Topic; Colonic Neoplasms; Disease Models | 2003 |
Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy.
Topics: Abdominal Neoplasms; Adenocarcinoma; Animals; Anticoagulants; Cell Adhesion; Cell Line, Tumor; Hepar | 2003 |
The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro.
Topics: Adenocarcinoma; Anticoagulants; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell | 2008 |
Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Anticoagulants; Dalteparin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle | 2007 |
A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Fibrinolytic Agents; Heparin, Low-Mol | 2013 |
Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids?
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Calcium; Cell Line, Tumor; Chemokine CXCL12; Chemokines, | 2007 |